Establishment Labs (ESTA) Investor Day 2025 summary

Strategic priorities and financial outlook

• 2025 revenue guidance is $205–$210 million, with US sales expected to exceed $35 million and mid-single digit growth outside the US.

• Operational efficiency initiatives include a ~30% reduction in operating expenses since 2023, with EBITDA positivity targeted for 2025 and cash flow positivity in 2026.

• Gross margins are projected to rise by 200–300 basis points, driven by US performance.

• Expansion of minimally invasive platforms (Preservé and Mia) is central to both US and international strategies, supporting market expansion and premium pricing.

• Reconstruction market entry is anticipated in 2026, with regulatory submissions planned for late 2025 and a full launch in early 2027, targeting a market with higher price points and stable growth.

Product innovation and clinical outcomes

• Motiva's portfolio includes SmoothSilk® surface technology, Ergonomix®, Flora, Preservé, Mia, and upcoming launches like Ergo2 and Diamond, supported by over 200 patents and 4M+ devices sold.

• Clinical data shows less than 1% device-related complications, with US IDE study reporting 0.5% capsular contracture, 0.6% rupture, and 8.8% reoperation at 5 years.

• Minimally invasive techniques (Preservé, Mia) preserve breast anatomy, reduce recovery time, and expand the candidate pool, especially among patients seeking subtle enhancements or those averse to traditional surgery.

• The innovation pipeline includes annual new technology or indication launches for the next 3–5 years, with Preservé tools launching in the US in 2026 and further expansion into gluteal augmentation (GEM).

• MRI-compatible tissue expanders (Flora) and RFID-enabled implants support advanced reconstruction and data collection, with significant clinical and operational advantages.

US market execution and commercial momentum

• Over 1,000 US practices and surgeons have adopted Motiva products, with more than 100 permanent consignments placed in targeted accounts.

• Q1 2025 US revenue was $6.2M; Q2 expected at $9.5–$10M, with full-year US revenue to meaningfully exceed $35M.

• 75%+ of orders processed via the Motiva Portal, streamlining customer experience.

• Significant brand awareness driven by direct-to-consumer, influencer campaigns, and high-profile endorsements, including Meghan Trainor.

• Over 5,000 patient leads and 120,000+ actions on the Motiva Surgeon Locator.